130 results
DEFA14A
APLS
Apellis Pharmaceuticals Inc
26 Apr 24
Additional proxy soliciting materials
4:08pm
of stockholders; 1.01 Paul Fonteyne 1.02 Stephanie Monaghan O'Brien 2. Ratification of the appointment of Deloitte & Touche LLP as our independent registered
S-8
kpjmrsrph7fn2gi od
27 Feb 24
Registration of securities for employees
7:35am
S-8
EX-23.2
x2hlpn
27 Feb 24
Registration of securities for employees
7:35am
8-K
7rjl 1oce
8 Jan 24
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
9:07am
8-K
EX-1.1
k2e9tvvijkq05gd
1 Nov 23
Entry into a Material Definitive Agreement
7:59am
424B5
o1vj2ejya ef
1 Nov 23
Prospectus supplement for primary offering
7:51am
8-K
EX-99.1
c36 whv22f4
5 Oct 23
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
7:15am
DEFA14A
69oyjgrar5i 09uou
21 Apr 23
Additional proxy soliciting materials
9:03am